Corvus Pharmaceuticals (CRVS) announced that the IND application submitted by its partner in China, Angel Pharmaceuticals, has been approved by the Center for Drug Evaluation, CDE, of the China National Medical Products Administration, NMPA, to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China. Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelitinib in greater China and is responsible for all expenses related to its development in China.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Holds Annual Stockholders Meeting
- Corvus Pharmaceuticals Reports Promising Phase 1 Trial Results
- Corvus announces new interim data from Phase 1 trial of soquelitinib
- Corvus Pharmaceuticals price target lowered to $11 from $12 at Mizuho
- Biotech Alert: Searches spiking for these stocks today